Introduction {#s1}
============

The shape of a face strongly depends on the geometry of skeletal elements directly under the skin, adipose tissue and muscles. Our adult cranial and, in particular, facial skeleton consists mostly of bony elements. Cartilaginous parts are rather minor. However, during embryonic development bone forms after the cartilage, and the initial phases of facial and skull shaping proceed with the cartilaginous skeleton only. The entire functional and evolutionary meaning of the chondrocranium, that is, the early cartilaginous elements of the embryonic skull, is not clear. Some parts of the chondrocranium will undergo endochondral ossification (for example, pre-sphenoid and basisphenoid, cribriform plate, Meckel´s cartilage, olfactory septum, nasal concha, labyrinth of ethmoid, vomer and tympanic bulla). However, the majority of the bones, especially in a facial compartment, will form in a close spatial association with the chondrocranium independently through dermal membranous ossifications ([@bib10]). Many questions, including how and from where molecular signals control the complex chondrocranial shape, and whether the geometry of the chondrocranium directs the shape of facial bones, are still unanswered.

Achondroplasia, a rare disease due to cartilage insufficiency, includes craniofacial malformations such as protruding forehead, low nasal bridge, maxillary hypoplasia, problems in the otolaryngeal system and macrocephaly as well as foramen magnum stenosis ([@bib54]). Prominent human and mouse achondroplasia phenotypes based on *Fgfr3* mutations suggest that a correctly shaped chondrocranium is essential for proper facial bone geometry and general facial outgrowth. However, *Fgfr3* is expressed also at membranous ossification sites (please see *Fgfr3*(mRNA) expression at E15, <http://developingmouse.brain-map.org/>), as well as in sutural osteogenic fronts ([@bib44]). Therefore, models involving *Fgfr3* do not allow for precise discrimination of cartilage or bone-dependent parts of the phenotype in affected subjects. Still, these effects strongly suggest that chondrocranium shape might be truly important for producing initial facial geometry and for influencing the formation of membranous bone on top of the cartilaginous template.

The facial chondrocranium is built by neural crest cells that populate the frontal part of the head and undergo multilineage differentiation. They give rise to cartilage, bone, fascia, adipose tissue, smooth muscle, pericytes, glia and neurons ([@bib55]; [@bib5]). Paraxial mesoderm also contributes to the chondrocranium in posterior basicranial and occipital locations. Collective behavior and differentiation of the neural crest and neural crest-derived ectomesenchyme is largely responsible for the future shape of the face ([@bib40]). However, the precise mechanisms governing this collective behavior, cartilage induction and shape-making are not fully understood, despite significant progress in the research field of cartilage and bone formation.

McBratney-Owen and Morris-Key with coworkers demonstrated that the complete chondrocranium (including the base of the skull) develops from 14 pairs of independently induced large cartilaginous elements that fuse together during later development ([@bib38]). Sculpting perfect geometries of such cartilaginous elements is a key developmental and regenerative process that accounts for the shape and integrity of our body. Current opinion holds that cartilage forms from condensing mesenchymal cells that are destined to become chondrocytes ([@bib44]). Mesenchymal condensations emerge in specific locations. Here, they somehow become shaped, grow and turn into cartilage that later expands until the initiation of endochondral or membranous ossification.

The frontonasal prominence and other facial regions are enriched in signaling systems. Activity in these systems leads to progressive induction and shaping of craniofacial structures, including chondrogenic mesenchymal condensations that turn into cartilage ([@bib40]). The signaling center located in the most anterior face, the so called FEZ (Frontonasal Ectodermal Zone), produces Sonic Hedgehog (SHH) and Fibroblast growth factor 8 (FGF8), which play important roles in facial shaping. FGF8, SHH and Bone Morphogenetic Proteins (BMPs) produced by FEZ regulate the behavior of ectomesenchymal tissue and participate in positioning of chondrogenic condensations inside of the embryonic face ([@bib15]; [@bib27]; [@bib66]). The mechanisms of facial cartilage induction that involve these molecules have received particular attention during recent years ([@bib21]; [@bib1]; [@bib7]; [@bib19]).

Another recent breakthrough brought up the fact that the brain itself can emit signals that influence facial shaping. Expression of *Shh* in the forebrain turned out to be important for the correct formation of FEZ and early steps of facial shaping in general ([@bib28]; [@bib14]).

Still, how these and other signaling centers synchronize in order to build the 3D shape of facial cartilaginous elements is not understood. The cartilaginous nasal capsule is the most anterior part of the chondrocranium. Together with Meckel's cartilage in the lower jaw, it constitutes an excellent model system to address questions concerning cartilage induction and shaping.

Here, using mild ablations of cartilage with tightly controlled genetic tools, we revealed that the shape of the nasal capsule is a key for the geometry and positioning of the facial bones and overall facial shape. Subsequently, with the help of numerous mouse mutants, specific contrasting techniques and micro-CT, we demonstrated that signaling centers in the developing brain and olfactory epithelium jointly and independently enable the induction of the nasal capsule in the embryonic face. Various genomic regulatory regions that direct the expression of *Shh* to the developing nervous system participate in the fine-tuning of the shape of the facial cartilaginous skeleton.

Results {#s2}
=======

Taking into account known achondroplasia facial phenotypes, we hypothesized that even minor changes in the facial cartilaginous template may lead to significant or even major changes in the overlaying membranous bone geometry and the overall facial shape. Thus, we performed mild time-controlled genetic ablation of early chondrocytes employing *Col2a1-CreERT2/R26DTA* mice and analyzed their facial development ([Figure 1](#fig1){ref-type="fig"}). We used a dose of 2.5 mg of tamoxifen administered at E12.5 and, in an alternative experiment, double injection at E13.5-E14.5 to avoid a strong phenotype with dramatic face shortening and brain shape distortion, and we analyzed the mutant embryos at E17.5 and E15.5 correspondingly ([Figure 1](#fig1){ref-type="fig"}). *Col2a1-CreERT2* is a well-established tool to target facial chondrocytes and their immediate progenitors. Tamoxifen was administered at early stages of facial development where no bone is present. Also, this *CreERT2* line does not recombine in osteoblasts or their progenitors in membranous ossification sites and, thus, cannot directly impinge on them ([Figure 1A--D](#fig1){ref-type="fig"}). Despite only mild cartilage reduction (mean 30,7% of the cartilage surface decrease at E15.5 and mean 35,2% at E17.5), the facial compartment of the *Col2a1-CreERT2^+/-^/R26DTA^+/-^*embryos appeared massively affected with short snout and distorted membranous ossifications ([Figure 1E--R](#fig1){ref-type="fig"}). Interestingly, the forming mandibular bone appeared shortened and widened at the same time, which cannot be explained only by the shortening of Meckel's cartilage ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). This fact suggests an interplay between cartilage and membranous bone that might involve signal-guided rearrangements in skeletogenic tissues. Thus, genetic ablations of COL2A1-producing pre-chondrocytes and chondrocytes revealed a different degree of cartilage loss in the nasal capsule and Meckel's cartilage, together with corresponding incremental dysmorphologies of membranous bones and face in general. These slight differences in the strength of the phenotype are likely attributed to the fine diversity of developmental stages within one litter receiving tamoxifen during a single injection into a mother ([Figure 1Q--R](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Thus, the geometry of the face and corresponding bony structures depend on the correct induction and shaping of a facial cartilage. This, in turn, is largely established at the level of chondrogenic mesenchymal condensations, as we recently demonstrated ([@bib32]). It is worth emphasizing that according to our previous study, the chondrogenic condensations are induced being pre-shaped ([@bib32]).

![Correct chondrocranium development is essential for shaping the embryonic face.\
(**A--C**) Genetic tracing induced at E12.5 in *Col2a1-CreERT2/R26Confetti* shows recombination in chondrocytes (**B**) only and not in a lineage of membranous bone osteoblasts and their progenitors (**C**), 25 µm cryo-sections (**A--D, G--H**) were imaged with a confocal microscope (**A--C**) or phase contrast microscope (**D, G--H**). (**D**) Traced sections have been stained using Alcian Blue (cartilage, blue) and von Kossa (brown, mineralized tissue). (**E--F**) Wild type (**E**) and *Col2a1-CreERT2/R26DTA* (**F**) embryos with cartilage being partially ablated as a result of tamoxifen injection (2.5 mg) at E12.5, both analyzed at E17.5. (**G--H**) Sagittal sections of the anterior head from wild type (**G**) and *Col2a1-CreERT2/R26DTA* (**H**) embryos stained with Alcian Blue (blue, stains for cartilage) and von Kossa staining (black, stains for mineralized bone tissue). Olfactory system is outlined by green dashed line for better orientation. Note that physiological growth of the cartilage sets the proper size of the facial compartment. (**I--O**) 3D-reconstructions of frontal chondrocranium together with bone and teeth primordia in control (**I, L, M**) and cartilage-ablated (**J, N, O**) embryos. (**K**) Best fit comparison of control (red) and cartilage-ablated (light green) 3D chondrocranium models. (**P**) 3D-reconstruction of frontal chondrocranium and formed cartilage including GOM Inspect software analysis of the mutant bone (**Q**) overview of analyzed mutants (injected with low dose of tamoxifen (2.5 mg) at both E13.5 and E14.5 and analyzed at E15.5) and formed bone in one representative control and three mutants (**R**) Bar-graphs showing the manual 3D segmentation of the surface area of cartilage. Data are obtained from three control samples and three mutant mice for (E15.5) and three control samples and one mutant sample with the most pronounced phenotype for (E17.5). The error bars show mean and standard deviation (SD). For the comparison, we used unpaired Student t-test (95% confidence interval −9974138 to −6056665). Raw data are available in [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.34465.004Figure 1---source data 1.Raw values of cartilage surface measurments corresponding to Graph in [Figure 1R](#fig1){ref-type="fig"}.](elife-34465-fig1){#fig1}

Consequently, we decided to analyze the molecular signals and their sources that induce these geometrically complex condensations. Several molecules were reported to have an impact on the cartilage induction, either on the condensation placement or on proper timing of cartilage-forming events ([@bib18]). Among those, SHH was shown to play a key role in the spatio-temporal induction of chondrogenic mesenchymal condensations ([@bib1]; [@bib8]; [@bib46]). We analyzed the expression of *Shh* in early and late developing mouse face with the help of the *Shh-Cre/GFP (B6.Cg-Shhtm1(EGFP/cre)Cjt/J)* model, and found that *Shh* is expressed in very discrete regions of the face between E11.5 and E14.5 at the time of induction of facial cartilages ([Figure 2](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). At the early stages (E11.5 and E12.5, see [Figure 2A--B](#fig2){ref-type="fig"}), the SHH + regions included forming olfactory epithelium (magenta), dental and oral epithelium (red), eyes (cyan) and brain (yellow). Interestingly, only certain regions of olfactory epithelium were SHH+ (see stained cryosections under the 3D models in [Figure 2](#fig2){ref-type="fig"}). Later on (at E13.5 and E14.5 -- [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), we detected additional SHH-producing structures such as whiskers (blue-green), tongue (not segmented) and salivary gland (blue). We assumed that there is a prerequisite for a certain minimal distance between *Shh*-expressing structures and forming cartilage of nasal capsule that enables the secreted molecule to reach the target and impose chondrogenic stimuli on mesenchymal cells. According to our results, the most probable pro-chondrogenic SHH-emitting structures in the face were the olfactory epithelium and the forebrain.

![*Shh* is expressed through the early facial development in distinct regions of the head.\
The expression pattern of *Shh* during developmental stages E11.5 (**A**) and E12.5 (**B**) in *B6.Cg-Shhtm1(EGFP/cre)Cjt/J*, segmented *Shh*-expression regions are color-coded and clarified in legend (**C**). Immunohistochemical (IHC) staining shows olfactory neuroepithelium and newly formed mesenchymal condensation as ERBB3 positive. White arrows point at GFP-expressing parts of various tissues. Red rectangle in (**A**) and (**B**) upper panel mark the olfactory neuroepithelium, yellow rectangle in (**B**) shows area magnified in the right bottom corner. White dotted line outlines the shape of mesenchymal condensation. IHC staining was performed on 20 µm cryosections and imaged using a confocal microscope.](elife-34465-fig2){#fig2}

To test if SHH emitted by these structures controls nasal capsule induction or influences its geometrical features, we analyzed a series of mouse mutants with a micro-CT-based 3D-visualization approach. To perform these 3D visualizations of the mesenchymal chondrogenic condensations, cartilage and bone, we utilized a soft tissue contrasting with phosphotungstic acid (PTA) followed by micro-CT scanning. Chelation of tungsten is uneven in various cell types and creates reliable contrast highlighting different tissues.

Firstly, to address whether the induction of distinct elements of the facial chondrocranium is not only timely regulated, but also has a discrete spatial aspect related to various sources of inductive signals, we genetically ablated *Shh* in the brain to test its role in facial cartilage induction. For this, we took advantage of *Nkx2.2-Cre/Shh ^floxed/floxed^* animals to delete *Shh* in the floor plate cells since the beginning of central nervous system (CNS) development and patterning. We analyzed two different stages: E12.5 as a stage of condensations of cartilaginous mesenchyme ([Figure 3](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} 'Interactive PDF') and E15.5 as a later stage of nearly fully formed chondrocranium with its rather final shape ([Figure 3](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} 'Interactive PDF'). This experiment resulted in an unexpected phenotype. It included a selective loss of a nasal septum together with heavily affected posterior part of the nasal capsule as detected at E12.5 ([Figure 3B--C,E--F](#fig3){ref-type="fig"}). The chondrogenic condensation corresponding to a forming septum failed completely, whereas the condensation of the posterior part of nasal capsule appeared incompletely induced. Additional changes were detected in the facial cartilage at E15.5, mainly represented by the missing midline groove ([Figure 3G--H](#fig3){ref-type="fig"}) and the absence of the very anterior part of nasal cartilage ([Figure 3H](#fig3){ref-type="fig"}). Additional changes included various malpositioned parts, fused nerve foramina and variations in shaping and bending of cartilage elements, as summarized in [Figure 3](#fig3){ref-type="fig"}. Notably, the mutant embryos analyzed at E12.5 and E15.5 presented with cleft palate. This could indicate that some clinical cleft palate cases might have their origin in disturbed brain-derived signaling ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}).

![*Shh* signal from the brain induces a posterior part of a nasal capsule.\
(**A**) Model of overall shape resulting from the excision of *Shh* from the floor plate using *Nkx2.2-Cre/Shh^floxed/floxed^* shows visible phenotype in the E12.5 mutant embryo comprising, for instance, from the cleft of upper lip, non-prominent or missing nasal vestibule and diminished curvature of the snout. (**B--C, E--F**) micro-CT scans-based 3D reconstructions of chondrogenic mesenchymal condensations in E12.5 mutant and control embryos. Note the missing posterior part of the developing nasal capsule and the missing septum in the mutant. (**D**) best-fit computed comparison of the overall shape and size of mutant and control embryo. (**G--H**) 3D models of chondrocrania of mutant (*Nkx2.2-Cre/Shh^floxed/floxed^*) and control embryo, analyzed at E15.5. Among the main differences are missing frontal part of nasal cartilage, missing lateral parts of developing nasal capsule, malpositioned asymmetric cartilage, not fully closed foramina for pervading nerves and vasculature and various disconnected cartilaginous segments. (**I**) Segmented cartilage and bones projected in the overall shape of the head of mutant (bottom) and control (upper) embryo. Note the malpositioned incisors in the maxilla of the mutant and missing part of the frontal nasal capsule formed by the bone. (**J**) Wall thickness analysis of the cartilages in the E15.5 head of mutant (bottom) and control (upper) embryo show no evident differences in the thickness of formed cartilage.](elife-34465-fig3){#fig3}

At the same time, the general geometry of the frontal part of facial chondrocranium remained almost unperturbed, thus, supporting the spatial modularity of cartilage induction in the face. The microstructure of the cartilage stayed normal, with fine borders defining bent cartilaginous sheets forming the major structure of the nasal capsule. The thickness of the cartilaginous sheets forming the capsule also remained comparable to that found in littermate controls ([Figure 3J](#fig3){ref-type="fig"}). These observations strongly suggested that the early stages of cartilage induction must be affected.

We also investigated bone formation in the area of the nasal capsule at E15.5 ([Figure 3I](#fig3){ref-type="fig"}). We observed missing parts in maxillary bones from mutants, and malpositioned incisors that were found more posteriorly on top of instead of being in the anterior part of the maxilla. At this stage and in this particular location, there was no endochondral ossification ongoing. However, according to micro-CT data, the bone was forming in the proximity and on top of the existing cartilaginous shape template. Thus, the facial chondrocranium is important for the correct formation of the membranous facial bones.

Recently it has been shown that the brain can influence facial shaping via *Shh,* acting presumably on the frontonasal ectodermal signaling zone (abbreviated as FEZ) ([@bib28]; [@bib14]). It is currently believed that FGF8, SHH and BMPs produced by FEZ regulate the behavior of ectomesenchymal tissue and participate in positioning of chondrogenic condensations inside of the embryonic face ([@bib15]; [@bib27]; [@bib66]). However, our data show that SHH emitted from the forebrain mostly affects the basicranial, posterior and septal parts of the facial chondrocranium without strong effects on the most anterior nasal capsule (including other soft tissues in general), which could be expected if the effects of a brain-derived SHH are entirely mediated by FEZ. Importantly, the major geometric structure of the mutant brain stays largely unchanged although it appears reduced in size. Thus, changes in brain shape are not likely to cause very selective influences on forming facial structures due to mere mechanical interactions ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}).

Finally, we analyzed the spinal column of the mutants and control embryos and found localized shape defects in the cervical vertebrae represented by incomplete transverse foramina (*foramina transversariae*) ([Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}). Notably, the defects in the nasal septum stayed confined only to the cartilage as a tissue. The septal chondrogenic condensations and cartilage were missing as apparent E12.5 and E15.5, whereas the soft tissues of the septum stayed in place ([Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}). Similarly, despite the cartilage defects clearly identified in spinal column, the other tissue types that were in close proximity to the defects did not show any difference from control. For instance, the vertebral arteries traversing the distorted cartilage of the transverse foramina appeared unaffected in *Nkx2.2-Cre/Shh ^floxed/floxed^* animals ([Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}).

Next, we determined the *Shh* expression in the forming olfactory epithelium and tested the role of the forming olfactory epithelium and olfactory neurons in the process of nasal capsule induction. The possibility that olfactory epithelium controls cartilage shaping is supported by the fact that the conchae of nasal labyrinth geometrically correlate with the folded structure of the olfactory epithelium, which they mechanically support.

A desired experimental setup that would allow us to target and genetically delete *Shh* from the olfactory epithelium does not exist. To define the importance of any signal derived from the olfactory epithelium we utilized *Six1* and *Six4* double knockout to specifically ablate the development of the olfactory epithelium ([@bib29]; [@bib33]). We analyzed *Six1/4* double mutant embryos at E18.5, that showed no olfactory structures, using the micro-CT method and performed a thorough comparison to wildtype littermates ([Figure 4](#fig4){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} 'Interactive PDF'). In these mutants which had markedly shortened noses, the roof of the nasal capsule was entirely missing. However, the septum and the posterior part of the capsule were relatively well-preserved ([Figure 4B--D](#fig4){ref-type="fig"}). An earlier analysis at E12.5, a stage when the majority of facial chondrogenic condensations come into place, showed that in double knockouts, the chondrogenic condensation corresponding to the nasal capsule roof is missing. The chondrogenic condensation corresponding to the nasal septum appeared non-fused at this stage and fused only later, as evident from E17.5 reconstructions. At the same time, the roof of the nasal capsule was never induced ([Figure 4---figure supplement 1A--D](#fig4s1){ref-type="fig"}). This is consistent with the prediction that a lack of the olfactory epithelium will prevent the induction of olfactory cartilages. Analyses of the bones showed a major change in the overall geometry, with prominent shortening along the anterior-posterior axis (brachycephalic-like appearance). Furthermore, we noticed a lack of mandibular incisors and an obvious asymmetry between left and right parts of the maxilla ([Figure 4E,J](#fig4){ref-type="fig"}).

![Signals from the olfactory epithelium induce the anterior part of the nasal capsule.\
(**A--J**) *Six1/Six4* double knock out mouse embryo compared to littermate control and analyzed at E18.5 using micro-CT and 3D-reconstruction. (**A, E, K**) overall shape and size of the mutant head is different from the control head, showing brachycephalic phenotype, bulging eyes, misshaped earlobes positioned more frontal and lower than the control embryo (**F, J, K**). Note also the left-right asymmetry of the snout of the mutant. (**B, G**) Wall thickness analysis of mutant (**B**) and control (**G**) embryo. (**C, H**) single plane from raw CT data shows missing olfactory neuroepithelium in the *Six1/Six4* double mutant and control. Note also missing nasal capsule but retained septum in the mutant. (**D--E, I--J**) various views on segmented 3D model of chondrocranium of mutant (**D--E**) and control (**I--J**) embryo. Among the obvious differences are missing roof and lateral parts of nasal capsule while the septum is preserved. (**L**) *Six1* single knock out mouse embryo analyzed at E18.5 using micro-CT 3D reconstruction (**M**) single plane cross-sections from raw CT of *Six1* single knock out E18.5 embryo.](elife-34465-fig4){#fig4}

In addition to the expression in olfactory placodes, *Six1* and *Six4* are expressed in different parts of early facial mesenchyme ([@bib33]; [@bib20]). The full knockout of *Six4* does not show any phenotype according to previously published data ([@bib45]). We therefore analyzed the full knockout of *Six1*, in which the olfactory epithelium is present, to see whether it will show a mesenchyme-driven phenotype in the nasal capsule roof. The analysis of E18.5 *Six1^-/-^* embryos demonstrated the presence of the nasal capsule roof as well as a septum. The phenotype in *Six1^-/-^* embryos mostly included a narrowing of the posterior nasal capsule with mild septal defects ([Figure 4L--M](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1E](#fig4s1){ref-type="fig"}).

This experiment provided a complementary, non-overlapping phenotype to the one with a nasal capsule resulting from the excision of *Shh* from the floor plate (*Nkx2.2-Cre/Shh^floxed/floxed^*). This suggests that solid cartilage elements in the forming face depend on joint activities of multiple regulatory zones (sources of SHH) during their induction and shaping.

To investigate if sensory neurons in the olfactory neuro-epithelium might be potential sources of SHH, we utilized *Ascl1* (*Mash1*) knock-out embryos ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). In these animals, major neurogenic transcriptional factor essential for olfactory neuron formation are missing, and very few olfactory sensory neurons are generated ([@bib22]; [@bib11]). We analyzed craniofacial structures in these mutants and found out that they did not demonstrate any gross abnormality despite their inability to develop large amounts of olfactory neurons. Hence, the sensory olfactory neurons are not critical cartilage-inducing sources, while the early olfactory epithelium, before the neurogenesis, is important for the formation of chondrogenic mesenchymal condensations.

To check if SHH from the brain and presumably from the olfactory epithelium acts directly on facial mesenchyme inducing chondrogenic differentiation or during cartilage growth, we analyzed embryos carrying a SHH-activity reporter *GBS-GFP* ([@bib6]) at different developmental stages ranging from E9 to E14.5. The GFP signal was detectable as expected in the forming palate, brain, spinal cord and tissues that are known to receive SHH input. However, we did not observe GBS-GFP activity in the chondrogenic mesenchymal condensations from the earliest chondrogenic stages E11.5-E12.5 onwards ([Figure 5A](#fig5){ref-type="fig"}). Consistently with this, lineage tracing in *Gli1-CreERT2/R26Tomato* mice injected with tamoxifen at E11.5 and analyzed at E17.5 showed sporadic patches of traced chondrocytes in the facial cartilages ([Figure 5B](#fig5){ref-type="fig"}). If the injection of tamoxifen was performed at E12.5 or later, these sporadic patches of labeled chondrocytes disappeared; that is we observed only very rarely scattered chondrocytes in other locations ([Figure 5B--C](#fig5){ref-type="fig"}). Analysis of the rare individual clones of chondrocytes resulting from labeling at E11.5 in *Gli1-CreERT2/R26Confetti* demonstrated that mesenchymal cells turn into chondroprogenitors that divide several times to generate clonal clusters of mature chondrocytes ([Figure 5C--D](#fig5){ref-type="fig"}). At later stages of tamoxifen administration, this was not observed, which is consistent with analysis of *Gli1-LacZ* embryos at E12.5, where the X-gal staining was confined to whisker pads and other peripheral locations. In situ hybridization (RNAscope) for other components of the Hedgehog pathway (including *Ptch1*(mRNA)*, Ptch2*(mRNA)*, Gli1*(mRNA)*, Gli2*(mRNA)) showed no enrichment within potential and actual chondrogenic areas ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). To functionally test if inhibition of SHH at chondrogenic stages will affect the development of facial cartilage, we administered SHH-inhibitor vismodegib ([@bib35]) at either E11.5, E12.5, or E13.5 and analyzed the embryos at E15.5. In line with predictions from expression analysis and SHH-activity reporter, we did not find striking abnormalities in nasal and Meckel´s cartilages from all treated and analyzed embryos (n = 4) ([Figure 6A](#fig6){ref-type="fig"}). At the same time, we observed the absence of palate and concomitant abnormalities in whiskers distributions in E11.5-to-E15.5 and E12.5-to-E15.5 stages of treatment, but not in E13.5-to-E15.5 stages. Indeed, in embryos treated between E11.5 and E12.5, the palatal shelves were severely reduced or missing ([Figure 6A--C](#fig6){ref-type="fig"}). This showed that SHH signaling in these embryos was inhibited to significant extents and also suggested that the action of SHH on patterning of the nasal capsule precedes the stage of chondrogenic condensations.

![Mapping of the expression of Gli1 and Shh signaling activity in mouse embryonic head.\
(**A**) Mapping of the activity of the SHH signaling in mouse embryonic head at E11.5, E12.5 and E13.5 prechondrogenic and early chondrogenic stages using *GBS-GFP* activity reporter. (**B**) Genetic tracing using *Gli1-CreERT2/R26Tomato* induced at E11.5 (upper panel) and E12.5 (bottom panel) and analyzed at E17.5. Dotted line outlines cartilaginous structures within the nasal capsule. White squares outline the magnified area. DRG = dorsal root ganglion, OLF = Olfactory system, MX = maxillar prominence, MD = mandibular prominence. TG = trigeminal ganglion. (**C**) Genetic tracing using *Gli1-CreERT2/R26Confetti*, induced at E11.5 and analyzed at E16.5 (left panel) and induced at E14.5 and analyzed at E17.5 (right panel) shows the contribution of Gli1-traced positive cells to the cartilaginous structures in the embryonic head. (**D**) Quantification of the contribution of Gli1-traced positive cells to the cartilage. (**A--C**) 20 µm cryosections were used for the IHC staining and analysis. A confocal microscope has been used for imaging.](elife-34465-fig5){#fig5}

![Effect of Vismodegib treatment on the size and structure of nasal cartilage.\
(**A**) Panel shows raw CT data, cross-sections from various planes from DMSO (control treatment), Vismodegib inhibitor administered at E11.5, E12.5 or E13.5, all analyzed at E15.5 (**B**) Raw CT cross-sections show absent/disrupted cartilaginous structures in Vismodegib-treated embryos (**C**) 3D reconstruction and comparison of inhibitor-treated (Vismodegib E11.5-E15.5) and control (DMSO-treated) embryos and their nasal capsules. Arrows point at differences in anatomy and overall geometry of the nasal capsule. Graph representation of overall cartilage change of inhibitor-treated embryos. Raw data are available in [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}. (**D**) 3D-reconstruction of the nasal capsule of *Shh* hypomorph (analyzed at E15.5 and E17.5) including wall thickness analysis.\
10.7554/eLife.34465.021Figure 6---source data 1.Raw values of cartilage measurements corresponding to Graph in [Figure 6C](#fig6){ref-type="fig"}.](elife-34465-fig6){#fig6}

Consistent with these results, which suggest an early pre-chondrogenic role of SHH signaling on nasal capsule patterning, the analysis of embryos homozygous for a hypomorphic *Shh* allele (*Shh-GFP,* here referred to as *Shh^Hypo^*), in which SHH signaling is constitutively reduced ([@bib68]; [@bib12]), revealed severe abnormalities in the facial cartilage ([Figure 6D](#fig6){ref-type="fig"} and [Figure 6---figure supplement 3](#fig6s3){ref-type="fig"}). The results of all genetic perturbations and treatments with drugs as well as their comparative phenotypes are summarized in [Figure 7](#fig7){ref-type="fig"}. Taken together, the effects of SHH on chondrogenic differentiation in the facial region are early and precede the first wave of chondrocyte differentiation that occurs between E11.5 and E14.5. These results are also consistent with the phenotype of *Six1/Six4* double knockout embryos at E12.5 ([Figure 4](#fig4){ref-type="fig"}), and corroborate the notion of an early pre-cartilage onset of the phenotype.

![llustration depicting the timeline of all experiments and the beginning of effects.\
The results of all genetic perturbations and treatments with drugs as well as their comparative phenotypes are summarized.](elife-34465-fig7){#fig7}

Tissue-specific expression of *Shh* is known to be controlled by multiple enhancers. Some, which may regulate *Shh* expression in the cranial region, have been characterized ([@bib65]; [@bib31]; [@bib50]). To modulate *Shh* expression in different craniofacial regions, we analyzed mutant mice carrying different rearrangements (deletions or inversions) with impacts on the distal regulatory landscape of *Shh* ([@bib59]). We paid specific attention to genomic regions where known and potentially unknown brain-specific enhancers (SBE, Shh Brain Enhancers) are located ([@bib31]; [@bib50]). Currently known SBEs (SBE2, SBE3, SBE4) localize between the *Shh* coding region and *mark 6b* ([@bib30]) (see scheme in [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Animals carrying an allele with the inversion of a large genomic region including known SBEs, *INV(−500 C1)*, demonstrated selectively localized mild defects in the nasal septum and also in the tips of Meckel's cartilage, but not in the roof of nasal capsule. This septum-specific phenotype appeared more pronounced in a homozygous *INV(−500 C1)* as compared to the heterozygous genotype. Interestingly, this allele does not change the relative position to *Shh* of most known enhancers that could be responsible for SHH-dependent facial skeletal development. The phenotype observed in this experiment showed that septal cartilage is sensitive to minor changes in SHH patterning signals that result from either removal of regulatory sequences distal to the C1 position, or indirect effects affecting distant enhancer-promoter- communications.

*INV(6b-C2)*, which removes additional enhancers required for ventral forebrain expression of *Shh* in E10.5 embryos ([Figure 6---figure supplement 1A--C](#fig6s1){ref-type="fig"}), showed much stronger phenotypes.

Such strong phenotypes are most likely due to disruption of the *Shh* TAD (Topologically Associating Domain), and displacement of major regulatory elements at a position which prevent their interaction with *Shh* ([@bib59]). Accordingly, *Shh* expression is much reduced in the forebrain of mutant embryos at E10.5 as evident from the results of in situ hybridization for *Shh* ([Figure 6---figure supplement 1A--C](#fig6s1){ref-type="fig"}).

Heterozygote *INV(6b-C2)* did cause minor defects in septum, while the same inversion over a full Shh deficiency (*DEL(−90 C2*) led to a strong holoprosencephaly similar to *Shh^Hypo^* ([Figure 6](#fig6){ref-type="fig"} and [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}. However, it was not as strong as a full *Shh* knockout, where only a proboscis is left.

In the mutants *INV(6b-C2) x DEL(−90 C2),* the nasal septum did not develop at all, and the rest of the nasal capsule (roof) was present although severely disturbed in shape. The gradual increase in severity of the malformations from *INV(−500 C1)* to *INV(6b-C2)* may indicate the presence of several distinct enhancers related to face morphology distal to position 6b (which likely includes yet uncharacterized enhancers). It could also mean that the efficiency of the interactions of the known enhancers (SBE2-4) with the *Shh* promoter is modulated by the presence of distal elements, which may contribute to organize the *Shh* TAD ([@bib59]). Both scenarios suggest the existence of other regulatory regions important for facial development including new potential SBEs based on the reduction of the *LacZ*-based *Shh*-expression reporter signal in the forebrain of mutant embryos at E10.5 ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}).

*DEL*(5-8) showed a powerful phenotype similar to the homozygous *INV(6b-C2)*. This, in a combination with previous phenotypes, reveals that the key regulatory regions essential for the facial cartilage patterning are located between *marks 6b* and *C1*. These regulatory regions are likely SBEs since the LacZ expression disappears from the forebrain of reporter embryos at E12.5 according to previous results ([@bib59]). *DEL(C1-Z)* did not show any gross abnormalities in the nasal capsule cartilage. Embryos carrying this mutation showed abnormal Meckel's cartilage and a generally affected mandible.

Taken together, local tuning of SHH expression by various enhancers (including brain-specific regulatory elements) seemingly controls discrete steps of chondrocranial patterning, which may represent a key evolutionary mechanism shaping animal snouts and faces.

Discussion {#s3}
==========

In addition to the obvious functional aspects, facial shape is important in many ways. For example, recognition of individual facial features assists social interaction and affects numerous important aspects of our everyday life ([@bib60]). Pathological conditions include a very wide spectrum of deficiencies, and may involve eating, breathing and speech impairments, emotional problems and low quality of life in general ([@bib16]). Here, we demonstrated that even fine and selective manipulations of a facial cartilage geometry and size (performed in *Col2-CreERT2^+/-^/R26DTA^+^* embryos) result in significant changes of adjacent membranous bones and facial shape. In turn, the facial cartilage geometry is controlled by the signals coming from neurosensory structures such as brain and olfactory epithelium. Altogether, these results might provide a new explanatory framework revealing how the integrated development of neural and non-neural tissues results in the precise and evolutionary adapted shape of the bony cranium and corresponding facial appearance.

Previously, Marcucio and Hallgrimsson laboratories demonstrated the co-variation of brain and face as well as the impact of brain-emitted SHH on avian facial development ([@bib26]; [@bib36]; [@bib47]; [@bib48]). Yet, the role of such brain-derived signals in cartilage and bone shaping has not been extensively investigated. According to our results, SHH, a key signal enabling cartilage induction, arrives from the floorplate of the brain, and the selective ablation of *Shh* in that area by non-inducible *Nkx2.2-Cre* causes a highly selective loss of the nasal septum cartilage. The soft non-cartilaginous tissue of the nasal septum, however, remains intact, rendering this part of the phenotype highly cartilage-specific. The roof of the nasal capsule stays nearly unaffected. The analysis at E12.5 stage suggested that this phenotype must be related to pre-chondrogenic, early SHH-dependent patterning signals enabling cartilage formation.

This reasoning is further supported by the line of experiments involving 'early on action' *Shh^Hypo^* embryos, which demonstrated a profound phenotype in the nasal capsule cartilage. This was in contrast to wild type embryos treated with the SHH-inhibitor Vismodegib strictly between chondrogenic stages (E11.5-E13.5). These embryos showed no significant phenotype in the nasal capsule cartilage. Correspondingly, lineage tracing with *Gli1-CreERT2* and expression analysis of SHH pathways members starting from E11.5 did not show any association with development of facial cartilages.

These cartilage-related results, where SHH-activity was not associated with facial chondrogenic differentiation, were dramatically different from those observed in palate-forming mesenchymal cells in the same experimental embryos. Unlike cartilage, the developing palate showed strong activity of the SHH-signaling reporter *GBS-GFP.* We also found high expression levels of SHH pathway members, including numerous traced progeny in *Gli1-CreERT2/R26Tomato* animals. As expected, in embryos treated with Vismodegib between E11.5-E12.5, the palate was almost missing, in contrast to contrary to the nasal capsule cartilage that stayed virtually intact. The presence of abnormal palate clefts in Vismodegib-treated and also in *Nkx2.2-Cre/Shh ^floxed/floxed^* embryos agrees with previous findings, which have established a general role of SHH in the patterning of the face and in development of pathological midfacial clefts ([@bib25]). Accordingly, ciliopathies and their animal models often demonstrate similar defects ([@bib9]; [@bib13]).

Thus, according to our results, SHH is not involved into facial chondrogenesis at stages when chondrogenic condensations form and convert into mature cartilage. Hence, the role of SHH is most likely indirect. Presumably, it is involved in the early patterning of facial ectomesenchyme, to create proper conditions for the sophisticated facial chondrogenesis that will start at later developmental stages. In line with this reasoning, the mode of action of SHH on chondrogenesis in non-facial locations, for example, during the development of axial skeleton, is indirect and based on SHH-dependent alterations of cell responses to BMPs in potentially pre-chondrogenic mesenchymal cells. Murtaugh et al. demonstrated that even a transient SHH signal was able to ensure the competent chondrogenic response of mesenchymal cells to BMPs ([@bib41]). In the case of the axial skeleton, such competence-changing action of SHH depends on the initiated and sustained expression of the transcriptional repressor *Nkx3.2*, which renders cells responsive to pro-chondrogenic actions of BMPs ([@bib42]). As shown by Zeng et al., expression of *Nkx3.2* is sufficient to induce SOX9, a major chondrogenic master regulator, and in the presence of BMPs, NKX3.2 and SOX9 could induce the expression of each other ([@bib69]). Finally, the sequential action of SHH and BMPs could induce SOX9. According to the public in situ database Allen Developmental Mouse Brain Atlas (<http://developingmouse.brain-map.org>), *Nkx3.2* shows distinct expression in a range of cranial cartilages or their future locations at pre-chondrogenic (E11.5) and chondrogenic (E13.5) stages. The knockout of *Nkx3.1* and *Nkx3.2* yields changes in the facial shape, as evident from [Figure 1](#fig1){ref-type="fig"} in Herbrand et al. ([@bib24]). Similar patterning effects of SHH in relation to chondrogenesis have previously been demonstrated during the development of serial tracheal rings reinforced with cartilage. SHH inactivation in ventral trachea resulted in a lack of tracheal segmentation which coincided with the loss of cartilage, while the upregulation of *Shh* resulted in cartilage overproduction and similar segmentation defects ([@bib51]). Altogether, this may suggest an analogous or similar mechanism of an indirect action of SHH on craniofacial chondrogenesis, especially in light of our results showing only minor and sporadic activity of SHH-signaling reporter in facial chondrogenic condensations or cartilage. Determination of the mechanisms behind SHH action in facial chondrogenesis, with a special focus on the position of the SHH-signal in the hierarchy of events leading to chondrogenic differentiation, is a key future direction. We anticipate that Single cell transcriptomics approaches ([@bib49]) will be applied to facial mesenchymal populations prior and during chondrogenesis. This should resolve cell signaling cascades with high precision along the developmental timeline, in similarity to pioneering studies utilizing this methodology in other tissue types ([@bib17]).

Complementary to the ablation of *Shh* by *Nkx2.2-Cre*, the loss of the olfactory epithelium in *Six1/Six4* double knockout mutants leads to the absence of the nasal capsule roof, while the nasal septum cartilage stays largely in place. Our data indicate that the loss of a nasal capsule roof in the double knockout condition is driven by the loss of nasal placodes (requiring both SIX1 and SIX4), which causes a collapse of olfactory epithelium. Despite the specific loss of nasal capsule roof, other cartilages appeared intact in locations corresponding to the expression sites of *Six1* and *Six4* (including Meckel's cartilage). The perfect match between the shape of cartilaginous olfactory turbines and the epithelium, as well as the coordinated time course of their development ([@bib32]), additionally support the notion that signals from the developing olfactory epithelium might enable the induction of adjacent cartilage. Still, these arguments cannot completely rule out the possibility that co-expressed *Six1* and *Six4* may have early roles during neural crest migration and early post-neural crest stages that might be important for the nasal roof formation. Taken together, our results provide strong support for the idea that a single solid cartilaginous element such as the nasal capsule can be induced by the combinatorial action of signals derived from several, in the present case, neural and neurosensory, locations. Notably, facial chondrogenic condensations are induced being 'pre-shaped'. Already at the earliest steps, they are laid down as highly complex 3D-geometries ([@bib32]). The induction of such 3D-shapes is unlikely to be achieved by signals from a single site and might require more sources including spatially opposed brain and olfactory structures. Since we were unable to validate that SHH from the olfactory placode or epithelium is the key factor that induces a nasal capsule roof, we cannot exclude that other signaling molecules participate during critical steps of facial cartilage induction. This will require further investigations.

During evolution of vertebrates, cartilages forming the neurocranium and the future upper jaw appear before Meckel's cartilage attains a function of a lower jaw skeleton, and the animals acquire articulated hinged jaws ([@bib53]). Therefore, one of the primeval functions of the neurocranial and frontal cartilages could be the encasement and protection of the neural and sensory compartments such as brain, eyes, ears and olfactory neurons. If that is the case, it is logical to reason that these neurosensory structures could emit cartilage-inducing signals and coordinate cartilage growth and shaping. Our experimental results reveal the key role of SHH from the developing brain in enabling the induction of a nasal capsule and basicranial cartilages, and, thus, support the aforementioned evolutionary hypothesis. The capacity of the developing olfactory epithelium to shape the cartilaginous support also favors this reasoning. Genetics-based prevention of neuronal differentiation in the olfactory epithelium (vial *Ascl1* knockout) does not interfere with shaping of the nasal capsule and confines the shaping role of presumably olfactory progenitors to the developmental period before their differentiation into the mature olfactory neurons. Alternatively, other cell types in the olfactory epithelium may play a cartilage-inducing role (olfactory glia, non-neurogenic epithelium).

In addition to the evolutionary aspect, the role of different neurosensory structures (mainly the brain) in coordinated cartilage induction may suggest a new connection between neurological and craniofacial symptoms in numerous genetic syndromes. Examples of such conditions are Williams syndrome, Down syndrome and others that are manifested by behavioral and morphological abnormalities in the central nervous system ([@bib57]; [@bib64]; [@bib61]; [@bib3]) (and reviewed by \[[@bib36]\]). Based on this reasoning, it is possible to envision a mechanistic connection between the fine aspects of a facial geometry and individual features of the human brain. An enormous facial variability is found among humans, which poses a question regarding the molecular and cellular mechanisms that underlie this variability. In difference to humans, non-human primates generally use variations in colored facial hairs to express their species, social status and sex in addition to body movements, voice expressions and scent ([@bib52]; [@bib2]). This brings us to speculate whether the loss of dense facial hairs during evolution of humans led to the development of a very broad range of various facial tissue-related features in order to compensate for the loss of facial hair-related communication and individual recognition. We hypothesize that one of those shape-tuning mechanisms could include flexible and individual modulation of SHH, an important patterning and shaping agent during the embryonic development that comes from different spatial sources including the developing brain.

Previous research has established the existence and position of some of the specific regulatory elements that direct the expression of *Shh* in the craniofacial epithelial linings (*MRCS1* and *MFCS4*, see ([@bib50]) for details) as well as in the floor plate and anterior forebrain (*SBE2* ((Shh Brain Enhancer 2)), *SBE3* and *SBE4 \[*[@bib65]; [@bib31]\]). In order to find out fine effects in facial cartilages as a result of activity by site-specific enhancers, we analyzed a variety of mutants with deleted and inverted genomic regions containing such regulatory elements (mutants created by François Spitz' laboratory \[[@bib59]\]). The inversion of the *−500* C1 genomic region including known CBEs showed localized defects within the nasal septum that incrementally increased from heterozygous to homozygous state without influencing nasal capsule roof shape. Similarly, the inversion of (*6b-C2)* region in a heterozygous state caused minor defects in septum, whereas the same inversion on the background of deletion of the entire regulatory region (*−90 C2*) appeared similar to *Shh^Hypo^* or even *Shh* knock out. This is explained by the translocation of TAD (see ([@bib59]) for details) and resulting 'isolation' of *Shh* coding part from head-specific regulatory regions located between positions six and *C2*. In this latter case (*INV(6b-C2)*), *Shh* expression was dramatically reduced in the anterior forebrain as compared to the control ([@bib59]).

Further analysis of more restricted *Shh* regulatory regions revealed that brain-specific and facial cartilage-related enhancers are confined within the region (*5-8*) and are at least partly responsible for the expression of *Shh* in the forebrain according to the loss of in situ hybridization signal in the forebrain of (*DEL(5-8)*) compared to controls. The deletion of this (*DEL(5-8)*) region resulted in severe facial malformation and collapse of the nasal capsule shape to the state resembling *Shh^Hypo^*. Despite that we clearly observed the misshaped nasal capsule roof in these embryos, the septum was completely gone similarly to (*DEL(−90 C2) x INV (6b-C2)*) mutants. Taken together, these results provide strong support to the discrete role of genomic regulatory regions directing the expression of *Shh* to the forebrain and, through this, affecting the patterning of septal, basicranial and other cartilages in the head.

Importantly, all analyzed embryos carrying mutated regulatory regions never demonstrated missing nasal capsule roof including severe (*DEL(−90 C2) x INV (6b-C2)*), (*DEL (5-8) HOMO*) and *Shh^Hypo^*. This might mean that we still do not know about the position of the corresponding regulatory regions targeting the expression of *Shh* to the olfactory epithelium or FEZ in the frontal face. The loss or inversion of regulatory regions resulting in mild septal defects did not affect the anterior nasal capsule, which might be independently patterned by FEZ. Similarly, the morphology of the anterior nasal capsule stayed relatively stable when septal cartilage disappeared in *Nkx2.2-Cre/Shh ^floxed/floxed^* animals. This suggests that the most anterior face including frontal facial cartilages might be indeed patterned by FEZ together with olfactory placodes independently from brain-derived signals. These results point towards the possibility that mouse FEZ can form and act independently of the CNS signaling center contrary to chick embryonic development ([@bib26]).

To summarize, it is possible that enhancer-dependent spatial and temporal regulations of *Shh* expression could be evolutionary tools to achieve the impressive variety of facial cartilage shapes in humans - a basis for facial individuality. Indeed, much attention has been focused on the role of enhancers in craniofacial evolution. Recently, by applying a combination of morphometry, molecular biology and mouse genetics, Attanasio et al. described numerous enhancers that are differentially active and take part in the development of a facial shape ([@bib4]). In line with this, mutations in the enhancers that control the expression of *Fgf8*, another cartilage-inducing factor ([@bib1]), also result in geometrical abnormalities of the nasal capsule ([@bib37]). It seems that many genes and pathways are involved in shaping the face ([@bib66]; [@bib28]; [@bib15]; [@bib27]). This is not surprising, since the facial shaping includes many stages that are pre-chondrogenic, chondrogenic (including induction, growth, remodeling of the cartilage) and osteogenic. Processes of isotropic and anisotropic growth of the skeletal structures also play important roles in achieving the final geometry of the facial region ([@bib32]). Despite such complexity and the enormous degree of spatio-temporal integration, the initial induction of cartilage guided by the brain and olfactory epithelium represents a key moment of facial skeleton formation. It may well also be an evolutionary substrate driving the diversity of faces and snouts. Consequently, the fine-tuning of patterning and cartilage-inducing signals in neurosensory structures deserves further attention, including explorations of the diversity of corresponding genetic regulatory regions in human and animal genomes.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type species\   Designation                      Source or reference                                                                                                                                                                                                            Identifiers   Additional information
  or resource                                                                                                                                                                                                                                                                                           
  ----------------------- -------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------- ------------------------
  Strain                  *Col2a1-CreERT2*                 [@bib43]                                                                                                                                                                                                                                     Received from\
                                                                                                                                                                                                                                                                                                        S. Mackem

  Strain                  *R26Confetti*                    <https://www.jax.org/strain/013731>                                                                                                                                                                                                          Received from\
                                                                                                                                                                                                                                                                                                        H. Clevers

  Strain                  *R26DTA*                         [@bib62]                                                                                                                                                                                                                                     Received from\
                                                                                                                                                                                                                                                                                                        Jackson

  Strain                  *Six1 KO*                        [@bib20]                                                                                                                                                                                                                                     Received from\
                                                                                                                                                                                                                                                                                                        P. Maire

  Strain                  *Six1/4 double KO*               [@bib20]                                                                                                                                                                                                                                     Received from\
                                                                                                                                                                                                                                                                                                        P. Maire

  Strain                  *Nkx2.2-Cre/Shhflx/flx*          [@bib67]                                                                                                                                                                                                                                     Received from\
                                                                                                                                                                                                                                                                                                        M. Matise

  Strain                  *Ascl1 (Mash1)*                  [@bib11]                                                                                                                                                                                                                                     Received from\
                                                                                                                                                                                                                                                                                                        U. Marklund

  Strain                  *B6.Cg-Shhtm1EGFP/creCjt/J*      [@bib23]                                                                                                                                                                                                                                     Received from\
                                                                                                                                                                                                                                                                                                        M. Hovorakova

  Strain                  *Gli1-CreERT2*                   <https://www.jax.org/strain/007913>                                                                                                                                                                                                          Received from\
                                                                                                                                                                                                                                                                                                        M.Kasper

  Strain                  *Gli1-lacZ*                      <https://www.jax.org/strain/008211>                                                                                                                                                                                                          Received from\
                                                                                                                                                                                                                                                                                                        M.Kasper

  Strain                  *Shh-GFP*                        <https://www.jax.org/strain/008466>\                                                                                                                                                                                                         Received from\
                                                           ([@bib12])                                                                                                                                                                                                                                   Jackson

  Strain                  *TgGBS-GFP*                      [@bib6]                                                                                                                                                                                                                                      Received from\
                                                                                                                                                                                                                                                                                                        A. Kicheva

  Strain                  *Rosa-CAG-LSL-tdTomato*\         <https://www.jax.org/strain/007914>                                                                                                                                                                                                          Received from\
                          *-WPRE*                                                                                                                                                                                                                                                                       M. Kasper

  Strain                  *INV-500-C1*                     F. Spitz ([@bib59])                                                                                                                                                                                                                          Received from\
                                                                                                                                                                                                                                                                                                        F. Spitz

  Strain                  *INV6b-C2*                       F. Spitz ([@bib59])                                                                                                                                                                                                                          Received from\
                                                                                                                                                                                                                                                                                                        F. Spitz

  Strain                  *Del-90-C2*                      F. Spitz ([@bib59])                                                                                                                                                                                                                          Received from\
                                                                                                                                                                                                                                                                                                        F. Spitz

  Strain                  *DELC1-Z*                        F. Spitz ([@bib59])                                                                                                                                                                                                                          Received from\
                                                                                                                                                                                                                                                                                                        F. Spitz

  Strain                  *DEL5-8*                         F. Spitz ([@bib59])                                                                                                                                                                                                                          Received from\
                                                                                                                                                                                                                                                                                                        F. Spitz

  Antibody                SOX9                             Sigma Aldrich, HPA001758                                                                                                                                                                                                                     one to 1000 in PBS-T\
                                                                                                                                                                                                                                                                                                        over night at RT

  Antibody                ERBB3                            RnD Systems, AF4518                                                                                                                                                                                                                          one to 500 in PBS-T\
                                                                                                                                                                                                                                                                                                        over night at RT

  Drug                    Vismodegib                       [@bib35]                                                                                                                                                                                                                                     0.1 mg/kg

  Software                IMARIS                           <http://www.bitplane.com/>                                                                                                                                                                                                                   

  Software                GOM Inspect                      [https://www.gom.com/de/3d-](https://www.gom.com/de/3d-software/gom-inspect.html)\                                                                                                                                                           
                                                           [software/gom-inspect.html](https://www.gom.com/de/3d-software/gom-inspect.html)                                                                                                                                                             

  Software                VGStudio Max                     [https://www.volumegraphics.com](https://www.volumegraphics.com/en/products/vgstudio-max.html)\                                                                                                                                              
                                                           [/en/products/vgstudio-max.html](https://www.volumegraphics.com/en/products/vgstudio-max.html)                                                                                                                                               

  RNAscope probes         Gli1 (311001), Gli2 (405771),\   [https://acdbio.com/rnascope%C2%](https://acdbio.com/rnascope%C2%AE-technology-novel-rna-situ-hybridization-research-platform)\                                                                                                              
                          Gli3 (445511), Smo (318411),\    [AE](https://acdbio.com/rnascope%C2%AE-technology-novel-rna-situ-hybridization-research-platform)[-technology-novel-rna-situ-](https://acdbio.com/rnascope%C2%AE-technology-novel-rna-situ-hybridization-research-platform)\                 
                          Ptch1 (402811) and Ptch2\        [hybridization-research-platform](https://acdbio.com/rnascope%C2%AE-technology-novel-rna-situ-hybridization-research-platform)                                                                                                               
                          (435131)                                                                                                                                                                                                                                                                      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mouse strains and animal information {#s4-1}
------------------------------------

All animal work were approved and permitted by the Local Ethical Committee on Animal Experiments (North Stockholm Animal Ethics Committee) and conducted according to The Swedish Animal Agency´s Provisions and Guidelines for Animal Experimentation recommendations. Genetic tracing mouse strain *Nkx2.2-Cre* was described previously ([@bib67]). *Col2a1-CreERT2* ([@bib45]) (obtained from the laboratory of S. Mackem, NIH) strains ([@bib43]) were coupled to *R26Confetti* mice that were received from the laboratory of Professor H. Clevers ([@bib56]). *DTA* strain ([@bib62]) (*B6.129P2-Gt(ROSA)26Sortm1(DTA)Lky/J*, The Jackson Laboratory) was coupled to *Col2a1-CreERT2. Six1* and *Six1/4* double KO embryos were generated as described already ([@bib20]; [@bib34]). *Nkx2.2-Cre/Shh^flx/flx^* embryos were received from the laboratory of Michael Matise. *Ascl1 (Mash1)* KO embryos were received from the laboratory of Ulrika Marklund. *B6.Cg-Shhtm1(EGFP/cre)Cjt/J* ([@bib23]) embryos were received from the laboratory of Maria Hovorakova (CAS). *Gli1-CreERT2* and *Gli1-lacZ* strains were obtained from the laboratory of Maria Kasper (Karolinska Institutet). *Gli1-CreERT2* was coupled with *R26Confetti* and *R26Tomato.*

The following strains were previously described: *Tg(GBS-GFP)* ([@bib6]), *Shh-GFP* (JAX stock \#008466 ([@bib12]). *Shh^Hypo^* embryos are homozygous for *Shh-GFP* and their morphological phenotypes are not affected by the presence or absence of the *Tg(GBS-GFP)* transgene. Strains were bred and maintained on 129/Sv background, in accordance with license BMWFW-66.018/0006-WF/V/3b/2016 granted by the Austrian BMWFW.

*Gli1-LacZ* (<https://www.jax.org/strain/008211>), *Gli1-CreERT2* (<https://www.jax.org/strain/007913>) and *Rosa-CAG-LSL-tdTomato-WPRE* (<https://www.jax.org/strain/007914>) were used under the ethical permit: number S40/13, granted by South Stockholm Animal Ethics Committee.

Mice of the relevant genotype were mated overnight, and noon of the day of the plug was considered as E0.5. To induce genetic recombination of adequate efficiency, pregnant females of relevant couplings were injected intraperitoneally with tamoxifen (Sigma T5648) dissolved in corn oil (Sigma C8267). Tamoxifen concentration ranged from 1.5 to 5.0 mg per animal to obtain a range of recombination efficiency. Mice were sacrificed with isoflurane (Baxter KDG9623) overdose or cervical dislocation, and embryos were dissected out and collected into ice-cold PBS. Subsequently, the samples were placed into freshly prepared 4% paraformaldehyde (PFA) and depending on the developmental stage and the application they were fixed for 3--24 hr at 4°C on a roller. Subsequently, for the purpose of microscopy analysis, the embryos were cryopreserved in 30% sucrose (VWR C27480) overnight at 4°C, embedded in OCT media (HistoLab 45830) and cut into 18 µm to 30 µm sections on a cryostat (Microm). Embryos designated for CT analysis were then stained according to the protocol described beneath.

Inhibition of hedgehog signaling {#s4-2}
--------------------------------

In order to inhibit SHH during embryonic development (stages E11.5 to E13.5), the pharmacological inhibitor Vismodegib ([@bib35]) was injected intraperitoneally at a dosage of 0.1 mg per g of bodyweight of the pregnant mouse. Embryos were collected at E15.5 and fixed in 4% formaldehyde in PBS solution for 24 hr at +4°C with slow rotation.

Histological staining {#s4-3}
---------------------

Slides were stained for mineral deposition using von Kossa calcium staining: 5% silver nitrate solution was added to the sections at a room temperature and exposed to strong light for 30 min. After that the silver nitrate solution was removed, and slides were washed with distilled water for 3 times during 2 min. 2.5% sodium thiosulphate solution (w/v) was added to the sections and incubated for five mins. Slides were again rinsed for 3 times during 2 min in distilled water. The sections were then counterstained using Alcian blue. Alcian blue solution (0.1% alcian blue 8GX (w/v) in 0.1 M HCl) was added to the tissue for 3 min at room temperature and then rinsed for 3 times during 2 min in distilled water. Slides were then transferred rapidly into incrementally increasing ethanol concentrations (20%, 40%, 80%, 100%) and incubated in 100% ethanol for 2 min. Finally, the slides were incubated in two xylene baths (for 2 min and then for 5 min) before mounting and analysis.

Immunohistochemistry, histological staining and EdU analysis {#s4-4}
------------------------------------------------------------

Frozen samples were sectioned at 18--30 µm depending on specific experiment. If needed, sections were stored at −20°C after drying 1 hr at room temperature, or processed immediately after sectioning. Primary antibodies used were: chicken anti-GFP (Abcam, 1:500, ab13970), rabbit anti-SOX9 (Sigma Aldrich, 1:1000, HPA001758), sheep anti-ERBB3 (RnD Systems, 1:500, AF4518). For detection of above-mentioned primary antibodies, we utilized 405, 488, 555 or 647-conjugated Alexa secondary antibodies produced in donkey (Invitrogen, 1:1000). Slices were mounted with 87% glycerol mounting media (Merck).

Fluorescent in situ hybridization (RNAscope) {#s4-5}
--------------------------------------------

E12.5 and E13.5 embryos were collected, embedded immediately in OCT and snap frozen on dry ice. Tissue blocks were stored at −20°C until further use. 8-[µ]{.ul}m-thick cryosections were collected on Superfrost Plus slides and stored at −20°C until further use. Fluorescent in situ hybridization was performed for the genes *Gli1* (311001)*, Gli2 (*405771)*, Gli3* (445511)*, Smo* (318411)*, Ptch1* (402811) and *Ptch2* (435131) using the RNAscope 2.0 Assay, reagents and probes according to manufacturer's instructions ([@bib63]). RNAscope probes were designed commercially by the manufacturer and are available from Advanced Cell Diagnostics, Inc. being protected by patent.

X-gal staining {#s4-6}
--------------

E11.5, E12.5 and E13.5 embryos were fixed in 4% formaldehyde in PBS solution for 2--3 hr at +4°C with slow rotation. Following washes with PBS, embryos were incubated in X-gal staining solution (1 mg/ml X-gal; 2 mM MgCl2; 0.5 M potassium ferrocyanide; 0.5 M potassium ferricyanide in PBS) at 37°C, overnight, with gentle agitation. Samples were washed twice, 20 min each time at room temperature in PBS and imaged whole mount. When necessary, we proceeded to cryoprotection in 30% sucrose in PBS and embedding in OCT medium.

Microscopy, volume rendering, image analysis and quantifications {#s4-7}
----------------------------------------------------------------

Confocal microscopy was performed using Zeiss LSM880Airyscan CLSM instruments. The settings for the imaging of Confetti fluorescent proteins were previously described ([@bib56]). Image analysis has been performed using IMARIS Software (Bitplane, Zurich, Switzerland). Before performing manual segmentations of cartilages and mesenchymal chondrogenic condensations on all representative samples, we assessed the phenotype and the stability of the phenotype using analysis of multiple embryos (typically 3--5 per condition) on histological sections as well as whole-mount assessments of facial morphology and including usage of tomographic slices. In case the phenotype was stable, the representative embryos underwent 3D segmentation process, otherwise we manually segmented facial cartilage and bone from all experimental embryos (in case of *Col2a1-CreERT2/R26DTA* or *Shh^Hypo^*, please see [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} and [Figure 6---figure supplement 3](#fig6s3){ref-type="fig"}). For embryonic day E17.5 *Col2a1-CreERT2/R26DTA,* we performed segmentations of the most affected embryo from the litter ([Figure 1I--P](#fig1){ref-type="fig"} and graph in R). Other litter mates were analyzed using cryo-sections only ([Figure 1E--H](#fig1){ref-type="fig"}). Since we did not investigate fine differences in shape of the nasal capsule and rather concentrated on missing structures (septum or nasal capsule roof), we did not analyze fine shape differences morphometrically in a quantitative way. In special cases, where relevant, we utilized shape fitting analysis using GOM Inspect tool. We did not use any special randomization or masking of embryos during experimental and control group allocations.

Tissue contrasting for µ-CT scanning {#s4-8}
------------------------------------

Staining protocol has been adapted and modified from the original protocol developed by Brian Metscher laboratory ([@bib39]). After embryo dissection in ice-cold PBS, the samples were fixed in 4% formaldehyde in PBS solution for 24 hr at +4°C with slow rotation. Subsequently, samples were dehydrated in incrementally increasing ethanol concentrations (30%, 50%, 70%), 1 day in each concentration to minimize the shrinkage of the tissue. Samples were transferred, depending on the embryonic stage, into 1.0--1.5% PTA (phospho-tungstic acid) in 90% methanol for tissue contrasting. The PTA-methanol solution was changed every 2--3 days. E12.5 embryos were stained for 7 days, E15.5 embryos for 3 weeks and E18.5 embryos for 7 weeks. The contrasting procedure was followed by rehydration of the samples by incubation in ethanol series (90%, 70%, 50% and 30%) and shipped to the CT-laboratory for scanning. There the rehydrated embryos were embedded in 0.5% agarose gel (A5304, Sigma-Aldrich) and placed in polypropylene conical tubes (0.5, 1.5 or 15 ml depending on the sample size to minimize the amount of medium surrounding it) and to avoid the movement artifacts during X-ray computer tomography scanning.

µ-CT analysis (micro computed tomography analysis) and 3D analysis {#s4-9}
------------------------------------------------------------------

The µ-CT analysis of the embryos was conducted using the laboratory system GE phoenix v\|tome\|x L 240 (GE Sensing and Inspection Technologies GmbH, Germany), equipped with a 180 kV/15W maximum power nanofocus X-ray tube and flat panel detector DXR250 with 2048 × 2048 pixel, 200 × 200 µm pixel size. The embryos were fixed in polyimide tubes by 1% agarose gel to prevent tomographic movement artifacts. The exposure time of the detector was 900 ms in every of 2000 positions. Three projections were acquired and averaged for reduction of the noise in µ-CT data. The utilized power of the tube was 11 W given by acceleration voltage of 60 kV and tube current of 200 μA. X-ray spectrum was filtered by 0.1 mm of aluminium plate. The voxel size of obtained volumes (depending on a size of an embryo head) appeared in the range of 5 µm - 7 µm. The tomographic reconstructions were performed using GE phoenix datos\|x 2.0 3D computed tomography software (GE Sensing and Inspection Technologies GmbH, Germany). The cartilage in the embryo head was segmented by an operator with semi-automatic tools within Avizo - 3D image data processing software (FEI, USA). The 3D segmented region was transformed to a polygonal mesh as a STL file. The mesh of the embryo head was imported to VG Studio MAX 2.2 software (Volume Graphics GmbH, Germany) for consequent modification of the mesh, like a surface smoothing, and 3D visualization. The software GOM Inspect V8 (GOM, Braunschweig, Germany) was implemented for comparisons of full shapes of the head. The triangular meshes of the surface of the heads represented by STL models were imported into the software, aligned and compared with parameters of maximum searching distance 1 mm and maximum opening angle 30°. All raw STL files are freely accessible via the following Dryad link: <https://doi.org/10.5061/dryad.f1s76f2>

The STL format can be opened with Paint 3D or Print 3D software.

Light sheet microscopy and sample clearing {#s4-10}
------------------------------------------

Whole heads from *Shh-GFP* embryos at E11.5 E12.5, E13.5 and E14.5 were cleared using a modified CUBIC protocol ([@bib58]). In brief, embryos were fixed by using 4% PFA in PBS for 4 hr at four degrees before incubating in CUBIC one solution (25% urea, 25% N,N,N′,N′-tetrakis-(2-hydroxypropyl) ethylenediamine and 15% Triton X-100) at 37°C under shaking conditions for 3 days. Subsequently, the samples were washed in PBS at RT. Next, samples were immersed in CUBIC two solution (50% sucrose, 25% urea, 10% 2,2′,2″-nitrilotriethanol, and 0.1% Triton X-100) and left shaking at RT for an additional 2--3 days before image acquisition.

Whole embryo head (E11.5--E14.5) GFP fluorescence images were acquired on a Light sheet Z.1 microscope (Zeiss) using a × 5 (EC Plan Neofluar 5×/0.16) detection objective,×5/0.1 illumination optics, and laser excitation at 488 nm. Samples were imaged in CUBIC two solution with a measured refractory index of 1.45. Each plane was illuminated from a single side of the sample. Whole images were obtained through tile scanning. 3D-rendered images were visualized with Arivis Vision4D for Zeiss (v. 2.11) or Imaris (v. 7.4.2, Bitplane).

Bitplane IMARIS software was subsequently used for 3D visualization and analysis of the light sheet tiles. By using the surface option in IMARIS the different parts of *Shh-GFP* have been highlighted.
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All data obtained including tomographic reconstructions will be freely available upon request since some datasets are considerably large (1TB and more) and depositing the full data is unfeasible. We have made a subset of the datasets available on the Dryad Digital Repository (<http://dx.doi.org/10.5061/dryad.f1s76f2>).

The following dataset was generated:
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Decision letter
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Richard M

Reviewing Editor

Memorial Sloan Kettering Cancer Center

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for sending your article entitled \"Signals from the brain and olfactory epithelium control shaping of the mammalian facial cartilage\" for peer review at *eLife*. Your article has been evaluated by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Marianne Bronner as the Senior Editor.

Major points:

1\) *Nkx2.2* ablation experiments

The genetic ablation of SHH in the floor plate with the *Nkx2.2* driver is perhaps the most elegant experiment in the paper, resulting in a clear phenotype that includes truncation of the nasal capsule and other craniofacial defects. However, investigating the developmental basis of the defect (by examining earlier stages, looking at cell death and proliferation, etc.) could clarify the role of CNS SHH in the patterning of the nasal capsule. Furthermore, the experiment by itself may not be sufficient to confirm direct regulation of mesenchymal condensations by SHH. The authors should examine *Shh* signaling activity in the nasal capsule either through the use of *Gli1-LacZ* reporter mice or by analyzing the expression of *Shh* pathway readouts (*Ptch1, Ptch2, Smo, Gli1*).

2\) *Col2a-DTA* ablation experiments

The authors should define what they mean by \"mild chondrocyte ablation\". It would be helpful to have a more quantitative and temporal understanding of how many cells are killed after the E12.5 induction in the DTA treatment and at what stage they are killed (as the difference between E13.5 to E15.5 can be dramatic). This would provide us with a better understanding of the precise stages at which the supposed SHH signal is required.

3\) A timeline of the genetic perturbations

It would be helpful to consolidate all the data with a timeline scheme depicting the steps in facial cartilage formation and place all the different genetic variants onto this scheme -- this would need to include the time point at which each set of mutants is first have an effect. For example, the *Nkx2.2* driver comes on much earlier than E12.5, and we know that there will be overall changes to the neuroepithelial tissues in this context. Similarly, the other mutants such as *Six1/Six4* are going to have major pathological effects much earlier than the cartilage condensation phases. Therefore, it seems difficult to eliminate the possibility that there is an earlier effect of SHH loss (e.g. changes in patterning or availability of mesenchymal tissues prior to cartilage condensation. This will of course raise the question of what is happening in the other mutants from E8+ through E12.5, but worth discussing.

4\) *Shh* expressing cells in the olfactory epithelium

The experiment involving the ablation of the olfactory epithelium is difficult to interpret given that the whole tissue is being targeted. Thus it is possible that other signals coming from these cells are required for the proper patterning of the nasal capsule. Furthermore, *Six1/Six4* are expressed in the neural crest lineage and the head mesenchyme at earlier stages of development and thus we cannot rule out that the effects observed are indeed cell autonomous. This should be addressed.

5\) Enhancer experiment

The enhancer experiments are tantalizing but very preliminary. First, the authors should clarify where these enhancers were published and what expression domains they produce. Have they been published (I could not locate a reference)? Furthermore, they would have to show how enhancer deletions results in changes of SHH expression. Unless the authors bridge the enhancer experiments with the previous data showing regional regulation of the nasal capsule, this section seems disconnected from the rest of the manuscript.

6\) The Discussion does the data a great disservice. There is a wealth of information in these animal models that is glossed over, in part because not enough detail is given for us to understand the different mutants (especially *Shh* enhancers). Furthermore, because there is never a direct comparison between the different lines, it is difficult to interpret the data in total. I think this is crucial because effectively, the conclusions are drawn upon a series of correlations -- if this is the bulk of the data, it will help the reader if all of the correlations are laid out in one unified vision at the end. Instead, the authors discuss some thoughts rationalising the evolution of the structures, which is rather a distraction from the findings. I don\'t see that it is necessary to make any evolutionary arguments; instead, I would like a bit more scholarship and context in the Discussion and some thought toward future directions.

10.7554/eLife.34465.028

Author response

> Major points:
>
> 1\) Nkx2.2 ablation experiments
>
> The genetic ablation of SHH in the floor plate with the Nkx2.2 driver is perhaps the most elegant experiment in the paper, resulting in a clear phenotype that includes truncation of the nasal capsule and other craniofacial defects. However, investigating the developmental basis of the defect (by examining earlier stages, looking at cell death and proliferation, etc.) could clarify the role of CNS SHH in the patterning of the nasal capsule. Furthermore the experiment by itself may not be sufficient to confirm direct regulation of mesenchymal condensations by SHH. The authors should examine Shh signaling activity in the nasal capsule either through the use of Gli1-LacZ reporter mice or by analyzing the expression of Shh pathway readouts (Ptch1, Ptch2, Smo, Gli1).

We followed the advice of reviewers and explored if the effect of *Shh* on chondrogenesis is direct or indirect and if it coincides with chondrogenic stages in the face. For this we performed a number of experiments including:

1\) The analysis of expression of SHH-pathway members using RNAscope (*Ptch1, Ptch2, Smo, Gli1, Gli2, Gli3*) and *Gli1-LacZ* reporter animals.

2\) Lineage tracing with *Gli1-CreERT2* coupled to *R26Tomato* and *R26Confetti* reporters.

3\) Analysis of SHH-pathway activity in mesenchymal chondrogenic condensations and cartilage by utilizing reporter *GBS-GFP* animals.

4\) Injections of SHH-inhibitor vismodegib at chondrogenic stages (E11.5-E13.5) and comparison of the phenotype with "non-inducible" *Shh hypomorphs (Shh^Hypo^*).

Altogether, the results of these experiments formed three new main figures (Figure 5, Figure 6 and Figure 7) as well as a number of corresponding supplementary figures (Figure 5---figure supplement 1, Figure 6---figure supplement 1, Figure 6---figure supplement 2 and Figure 6---figure supplement 3). These data demonstrated that SHH plays a pre-chondrogenic and, most likely, patterning role that is not directly involved in facial cartilage differentiation.

In the initial version of the manuscript we focused on the brain and olfactory epithelium as centers directing cartilage development, and did not claim that SHH has a direct and selective effect on the cartilage development in the face. With the new results that we incorporated in the revised version, we explicitly clarify that the time-window of *Shh* activity occurs prior to the chondrogenic stages. This new finding suggests that *Shh*-induced pattern or secondary signal is involved in cartilage differentiation -- possibilities that can be investigated in future studies.

Here is how we describe new results in the text of the Results section:

"To check if SHH from the brain and presumably from the olfactory epithelium acts directly on facial mesenchyme inducing chondrogenic differentiation or during cartilage growth, we analyzed embryos carrying a SHH-activity reporter *GBS-GFP*^27^ at different developmental stages ranging from E9 to E14.5. \[...\] These results are also consistent with the phenotype of *Six1/Six4* double knockout embryos at E12.5 (Figure 4), and corroborate the notion of an early pre-cartilage onset of the phenotype."

> 2\) Col2a-DTA ablation experiments
>
> The authors should define what they mean by \"mild chondrocyte ablation\". It would be helpful to have a more quantitative and temporal understanding of how many cells are killed after the E12.5 induction in the DTA treatment and at what stage they are killed (as the difference between E13.5 to E15.5 can be dramatic). This would provide us with a better understanding of the precise stages at which the supposed SHH signal is required.

We agree and we followed the advice of the reviewers and defined the proportion of cartilage loss in presented nasal capsules from the DTA animals. We also performed new experiments (collecting embryos at earlier stage for the analysis -- this time E15.5) and analyzed them. For this, we quantified the surface and volume of nasal capsule cartilage in control and DTA embryos analyzed at E15.5 and E17.5. For E17.5, the loss of cartilage in DTA sample was mean 30,7% of the cartilage surface decrease at E15.5 and mean 35,2% at E17.5. The new results can be found in Figure 1 and Figure 1---figure supplement 1.

The cartilage of the nasal capsule is fully set for the first time only at E15.5 (before that different parts are generated from chondrogenic condensations, see our paper Kaucka et al., 2017), and, thus, in the new experiment with another scheme of treatment aimed at higher cartilage loss, we analyzed the nasal capsule at E15.5 and not at E17.5. The principal results were consistent with the original experiment and showed how bone development becomes affected. Despite the reduction of nasal capsule cartilage, the membranous bones were induced adjacently in a tight association with chondrocranial parts. Please see Figure 1P,Q,R.

> 3\) A timeline of the genetic perturbations
>
> It would be helpful to consolidate all the data with a timeline scheme depicting the steps in facial cartilage formation and place all the different genetic variants onto this scheme -- this would need to include the time point at which each set of mutants is first have an effect. For example, the Nkx2.2 driver comes on much earlier than E12.5, and we know that there will be overall changes to the neuroepithelial tissues in this context. Similarly, the other mutants such as Six1/Six4 are going to have major pathological effects much earlier than the cartilage condensation phases. Therefore, it seems difficult to eliminate the possibility that there is an earlier effect of SHH loss (e.g. changes in patterning or availability of mesenchymal tissues prior to cartilage condensation. This will of course raise the question of what is happening in the other mutants from E8+ through E12.5, but worth discussing.

We generated an illustration (Figure 7) that depicts the timeline of all experiments and the beginning of effects. We cross-compare the phenotypes in Results and also in Discussion, so there is a clarity of when the action of mutation takes place and how different conditions are similar to each other or different.

> 4\) Shh expressing cells in the olfactory epithelium
>
> The experiment involving the ablation of the olfactory epithelium is difficult to interpret given that the whole tissue is being targeted. Thus it is possible that other signals coming from these cells are required for the proper patterning of the nasal capsule. Furthermore, Six1/Six4 are expressed in the neural crest lineage and the head mesenchyme at earlier stages of development and thus we cannot rule out that the effects observed are indeed cell autonomous. This should be addressed.

We agree and understand the reviewer's concerns. This is indeed great advice, and we discussed this moment extensively. It might be good to mention that we never claimed that it is SHH from the olfactory epithelium that induces the nasal capsule roof. Targeting *Shh* exclusively in the nasal placode is currently impossible. In the revised version of the manuscript, we discussed this issue in a more clear way since we totally agree that other signals derived from olfactory placode in principle can guide the development of nasal capsule roof.

"The induction of such 3D-shapes is unlikely to be achieved by signals from a single site and might require more sources including spatially opposed brain and olfactory structures. \[...\] This will require further investigations."

We provided additionally new data by generating and checking the key early stage of *Six1/Six4* double knockout (E12.5) and also by exploring a single knockout of *Six1 (Six4* knockout showed no phenotype). Here is the new text that we have in a revised version of the manuscript:

"In addition to the expression in olfactory placodes, *Six1* and *Six4* are expressed in different parts of early facial mesenchyme (Kobayashi et a., 2007; Grifone et al., 2005. \[...\] The phenotype in *Six1^-/-^* embryos mostly included a narrowing of the posterior nasal capsule with mild septal defects (Figure 4L,M and Figure 4---figure supplement 1E)."

"Complementary to the ablation of *Shh* by *Nkx2.2-Cre*, the loss of the olfactory epithelium in *Six1/Six4* double knockout mutants leads to the absence of the nasal capsule roof, while the nasal septum cartilage stays largely in place. \[...\] Already at the earliest steps, they are laid down as highly complex 3D-geometries (Kaucka et al., 2017)."

> 5\) Enhancer experiment
>
> The enhancer experiments are tantalizing but very preliminary. First, the authors should clarify where these enhancers were published and what expression domains they produce. Have they been published (I could not locate a reference)?

This is clarified in the main text. The initial discovery of these genomic regulatory regions is described in a recent manuscript from Francois Spitz laboratory (Symmons et al., 2016).

> Furthermore, they would have to show how enhancer deletions results in changes of SHH expression. Unless the authors bridge the enhancer experiments with the previous data showing regional regulation of the nasal capsule, this section seems disconnected from the rest of the manuscript.

We did our best to run more experiments and to show the plethora of the phenotypes that explain more clearly now how brain-specific *Shh* enhancers influence facial cartilage development. For the most critical mutations of *Shh* regulatory regions, we either report *Shh-LacZ* reporter data showing the shift of *Shh* expression in the forebrain or we cite the data of this kind obtained and published previously. In any case, we decided to move all data about enhancers to the supplementary information in this manuscript because of its accessory function.

Here are the major updated results also outlined in two supplementary figures (Figure 6---figure supplement 1 and Figure 6---figure supplement 2):

"Tissue-specific expression of *Shh* is known to be controlled by multiple enhancers. Some, which may regulate *Shh* expression in the cranial region, have been characterized (Yao et al., 2016; Jeong et al., 2006; Sagai et al., 2009). \[...\] Taken together, local tuning of SHH expression by various enhancers (including brain-specific regulatory elements) seemingly controls discrete steps of chondrocranial patterning, which may represent a key evolutionary mechanism shaping animal snouts and faces."

> 6\) The Discussion does the data a great disservice. There is a wealth of information in these animal models that is glossed over, in part because not enough detail is given for us to understand the different mutants (especially Shh enhancers). Furthermore, because there is never a direct comparison between the different lines, it is difficult to interpret the data in total. I think this is crucial because effectively, the conclusions are drawn upon a series of correlations -- if this is the bulk of the data, it will help the reader if all of the correlations are laid out in one unified vision at the end.

We expanded on the direct comparisons between the relevant mutant lines and we also added a new whole figure outlining the phenotypes and timing of effects (see Figure 7).

> Instead, the authors discuss some thoughts rationalising the evolution of the structures, which is rather a distraction from the findings. I don\'t see that it is necessary to make any evolutionary arguments; instead, I would like a bit more scholarship and context in the Discussion and some thought toward future directions.

We agree and we expanded the discussion towards molecular mechanism of SHH action on chondrogenesis, as well as provided some additional lines about future directions. We also kept the evolutionary tilt in the Discussion text since we hope that our findings will be considered important for EvoDevo aspect of craniofacial research.

[^1]: These authors contributed equally to this work.
